Revenio Group

13.80 EUR

+2.22 %

14,321 following
Corporate customer

REG1V

NASDAQ Helsinki

Medical Equipment & Services

Health Care

+2.22 %
-27.52 %
-27.37 %
-38.39 %
-40.13 %
-50.36 %
-61.67 %
-77.74 %
+626.32 %

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more
Market cap
368.2M EUR
Turnover
1.08M EUR
P/E (adj.) (26e)
16.82
EV/EBIT (adj.) (26e)
18.97
P/B (26e)
1.88
EV/S (26e)
3.24
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
20.00 EUR
Updated
29.04.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 29.04.2026

Latest extensive report

Released: 21.01.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.8
2026

Interim report Q2'26

29.10
2026

Interim report Q3'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
By the way, here is one nugget of information from yesterday that I don’t think was in the report or the interview. People here have also been asking why management isn’t buying if it’s such a good deal. The short answer is because the lawyers are saying it’s better if you don’t ...
4/29/2026, 2:53 PM
by Juha Kinnunen
84
I’ve been involved in Revenio’s investment story for over 10 years. A story of an exceptional product. It’s still hard for me to understand the business case for this acquisition from the perspective of an ordinary shareholder. I understand that for the major owner and management...
4/28/2026, 8:03 PM
by Seuraaja
49
It was asked in Revenio’s conference call; the answer was that they cannot.
4/29/2026, 6:01 AM
by Juha Kinnunen
36
Thanks for the informative interview, and it was indeed good to hear from someone other than just Toijala. I ended up buying based on that. I like that they want to grow; the growth room of the “old” Revenio was clearly starting to reach its limits, and with this product combo, they...
4/29/2026, 7:56 AM
by Larsson
35
New report: Inderes Revenio Q1'26: Osta ja odota - Inderes Markkinan epäusko Visionix-yritysostoon liittyen tarjoaa poikkeuksellisen hyvän tuotto-odotuksen lähivuosille. These acquisitions are always nerve-wracking, and for good reason… It’s difficult to get all the desired synergies...
4/29/2026, 6:00 AM
by Gwertheney
18
My view, and likely the market’s as well, is that margins will be under more intense pressure than what is projected in, for example, Juha’s report. It’s down 25% since my sale; a painful but necessary exit. Once again, a poor major shareholder proves that we are not in the same ...
4/29/2026, 7:51 AM
by Latela
11
As a thought experiment: what would happen to the share price if the deal fell through? A few million in wasted money. Lost opportunities? The share price would collapse further; it certainly wouldn’t recover. The smaller player acquired the larger one. It took a clear risk, of course...
4/29/2026, 5:43 AM
by Sissos
10
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.